Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Gw Pharma ADR (GWPH)

Gw Pharma ADR (GWPH)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,795,676
  • Shares Outstanding, K 30,922
  • Annual Sales, $ 311,330 K
  • Annual Income, $ -9,020 K
  • 60-Month Beta 1.87
  • Price/Sales 12.46
  • Price/Cash Flow N/A
  • Price/Book 5.47

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -0.53
  • Number of Estimates 10
  • High Estimate 0.12
  • Low Estimate -0.84
  • Prior Year -0.78
  • Growth Rate Est. (year over year) +32.05%

Price Performance

See More
Period Period Low Period High Performance
1-Month
96.10 +27.73%
on 05/01/20
134.35 -8.63%
on 05/26/20
+18.45 (+17.69%)
since 04/29/20
3-Month
67.98 +80.57%
on 03/17/20
134.35 -8.63%
on 05/26/20
+20.44 (+19.98%)
since 02/28/20
52-Week
67.98 +80.57%
on 03/17/20
182.05 -32.57%
on 06/04/19
-58.26 (-32.19%)
since 05/29/19

Most Recent Stories

More News
CBD Oil Extract Market Size, Industry Share, Growth, Trends, supplier, Demand, Regional Analysis, Top Manufactures-Kazmira, FOLIUM BIOSCIENCES, HempLife Today, CBD American Shaman, PharmaHemp

(MENAFN - CDN Newswire) and Forecast to 2027 is the latest research study released by DBMR evaluating the market, highlighting opportunities, risk side analysis, and leveraged with strategic and tactical...

ACB.TO : 19.27 (-9.10%)
GWPH : 122.75 (-2.16%)
Non-opioid Pain Treatment Market 2020 Break Down by Top Companies, Applications, Challenges, Opportunities and Forecast 2026

The report covers analysis on regional and country level market dynamics. The scope also covers competitive overview providing company market shares along with company profiles for major revenue contributing...

AGN : 193.02 (+0.02%)
ACB.TO : 19.27 (-9.10%)
HEMP : 0.0069 (-2.82%)
WEED.TO : 24.21 (-20.80%)
GWPH : 122.75 (-2.16%)
MJNA : 0.0250 (-7.41%)
ACB : 14.08 (-8.21%)
What's in Store for GW Pharmaceuticals (GWPH) in Q1 Earnings?

GW Pharmaceuticals (GWPH) might have registered slower international sales growth from procedural deferrals due to coronavirus pandemic in Q1.

AMN : 44.36 (-3.31%)
GWPH : 122.75 (-2.16%)
BWAY : 7.80 (-0.13%)
HCAT : 27.14 (+0.33%)
Medical Cannabis Market Report 2020: Industry Trends, Share, Size, Demand, COVID-19 Impact Analysis, And Future Scope

Global Medical Cannabis Market Report by Derivative (Cannabidiol (CBD), Tetrahydrocannabinol (THC), Others), Species (Indica, Sativa, Hybrid), Application (Cancer, Arthritis, Migraine, Epilepsy, Others),...

APHA : 4.23 (-1.86%)
ACB.TO : 19.27 (-9.10%)
CBDS : 0.6250 (-7.27%)
INSY : 0.29 (unch)
MEDFF : 18.8100 (-0.37%)
CNAB : 0.0165 (-65.63%)
GWPH : 122.75 (-2.16%)
ACB : 14.08 (-8.21%)
Outlook Therapeutics Bolsters Clinical and Commercial Expertise with Two Key Appointments to Board of Directors

-- Internationally renowned ophthalmologist, Gerd Auffarth, MD, ranked as one of the "100 most influential personalities in ophthalmology worldwide" in the 2020 Power List published by The Ophthalmologist...

AGN : 193.02 (+0.02%)
OTLK : 1.0200 (+0.99%)
GWPH : 122.75 (-2.16%)
RVNC : 20.90 (-1.97%)
KRYS : 51.41 (+2.06%)
Antiepileptic Drugs Market to Reach USD 20.33 Billion by 2026; Rising Production of Innovative Drugs to Boost Growth: says Fortune Business Insights(TM)

The global antiepileptic drugs (AED) market is set to gain traction from the ever-increasing initiatives by manufacturers for producing novel and generic drugs for patients. Patents of numerous second...

GWPH : 122.75 (-2.16%)
PFE : 38.19 (+0.03%)
CBD Oil Extract Industry Size, Market Share, Growth, Trends Analysis, Value, Industry Leaders- Aurora Cannabis, MARICANN, Tilray, Tikun Olam, The Cronos Group, HempLife Today: Says DBMR Analyst

Size, Share, Growth, Trends, Market Analysis by Source Type (Hemp, Marijuana), Distribution Channel (B2B, B2C), End-Use (Medical, Personal use, Pharmaceutical, Wellness), Country (United States, Europe,...

APHA : 4.23 (-1.86%)
ACB.TO : 19.27 (-9.10%)
GWPH : 122.75 (-2.16%)
First Week of November 20th Options Trading For GW Pharmaceuticals (GWPH)

Investors in GW Pharmaceuticals plc saw new options become available this week, for the November 20th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is...

GWPH : 122.75 (-2.16%)
Legal Marijuana Market Overview, New Opportunities & SWOT Analysis by 2025

This intelligence report provides a comprehensive analysis of the . This includes Investigation of past progress, ongoing market scenarios, and future prospects. Data True to market on the products, strategies...

APHA : 4.23 (-1.86%)
ACB.TO : 19.27 (-9.10%)
GWPH : 122.75 (-2.16%)
GW Pharmaceuticals and Greenwich Biosciences Announce FDA Acceptance of sNDA Filing with Priority Review for EPIDIOLEX(R) (cannabidiol) in the Treatment of Seizures Associated with Tuberous Sclerosis Complex

GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, along with its U.S. subsidiary Greenwich Biosciences, Inc.,...

GWPH : 122.75 (-2.16%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Trade GWPH with:

Business Summary

GW Pharmaceuticals plc is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company's lead product, Sativex is used for the treatment of MS symptoms, cancer pain, and...

See More

Key Turning Points

2nd Resistance Point 125.78
1st Resistance Point 124.26
Last Price 122.75
1st Support Level 121.24
2nd Support Level 119.74

See More

52-Week High 182.05
Fibonacci 61.8% 138.48
Fibonacci 50% 125.01
Last Price 122.75
Fibonacci 38.2% 111.55
52-Week Low 67.98

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar